InspireMD, which has headquarters in both Boston and Tel Aviv, also finished consolidating its manufacturing in Israel. Trimming Israeli operations was the 1st step in a long term "manufacturing upgrade," the company said.
InspireMD, which makes embolic protection stents, is pouring resources into a series of trials evaluating its MGuard device. MGuard is a stent specifically designed for heart attack patients.
Results from the 12-month Master trial are slated to come out next month; the company just opened enrollment in a Master II trial in the U.S. and Europe.
"We look forward to working with InspireMD as the Company prepares for increased demand for its MGuard stent technology throughout Europe," HealthLink Europe president Rick Hughes said in prepared remarks.